J. Stöhlmacher

A phase I/IIa study of the mRNA-based cancer immunotherapy CV9201 in patients with stage IIIB/IV non-small cell lung cancer

Martin Sebastian, Andreas Schröder, Birgit Scheel et al. · Cancer Immunology Immunotherapy · 2019 · 204 citations · Full text

Medicine, Immunology, Oncology +12

Cetuximab, fluorouracil and cisplatin with or without docetaxel for patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (CeFCiD): an open-label phase II randomised trial (AIO/IAG-KHT trial 1108)

Konrad Klinghammer, Thomas Gauler, Andreas Dietz et al. · European Journal of Cancer · 2019 · 30 citations

Medicine, Oncology, Chemotherapy +9

An analysis of safety in patients (pts) with recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) receiving chemotherapy (CT) with or without panitumumab (pmab) in a phase III clinical trial (SPECTRUM)

J. B. Vermorken, J. Stöhlmacher, Eric Winquist et al. · Journal of Clinical Oncology · 2009 · 23 citations

Medicine, Oncology, Pharmacology +17

Upfront FOLFOXIRI+bevacizumab followed by fluoropyrimidin and bevacizumab maintenance in patients with molecularly unselected metastatic colorectal cancer

Alexander Stein, Djordje Atanackovic, Bert Hildebrandt et al. · British Journal of Cancer · 2015 · 19 citations · Full text

Medicine, Oncology, Pharmacology +10

Safety and Efficacy of Panitumumab (pmab) in HPV Positive (+) and HPV Negative (−) Recurrent/metastatic (R/M) Squamous Cell Carcinoma of the Head and Neck (SCCHN): Analysis of the Phase 3 SPECTRUM Trial

Jan B. Vermorken, J. Stöhlmacher, Kelly S. Oliner et al. · European Journal of Cancer · 2011 · 15 citations

Medicine, Oncology, Pharmacotherapy +12